Urology · Overactive Bladder
The FDA's approval of a generic version of Mirabegron by Deva Holding AS signifies increased competition in the overactive bladder market. This could impact pricing strategies and market share for existing branded products, necessitating close monitoring by portfolio teams.
Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.
Last run 7/12/2026, 12:32:25 AM
Assessment confidence: 56% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.
The FDA's approval of a generic version of Mirabegron by Deva Holding AS signifies increased competition in the overactive bladder market. This could impact pricing strategies and market share for existing branded products, necessitating close monitoring by portfolio teams. Regulatory context from FDA (FDA AP — MIRABEGRON (ORIG)) supports the near-term read. Assessment grounded in 12 ranked evidence items (3 high-relevance).
Portfolio teams should assess the impact of this generic entry on pricing and market share for existing Mirabegron products. The strongest clinical anchor is Shaping Community-based Pathway to Improve TB Surveillance Among African and Hindustan Immigrants Experiencing Vulnerabilities (ClinicalTrials.gov), moderate corpus alignment. In Urology · Overactive Bladder, 2 regulatory and 1 competitive items passed relevance filtering for Mirabegron.
The most relevant competitive pressure comes from U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility (Pfizer) — sponsor/company relevance (pfizer). This approval introduces a generic version of Mirabegron, potentially increasing competition in the overactive bladder market.
Regulatory risk is concentrated around FDA AP — MIRABEGRON (ORIG) (FDA). Entity match (mirabegron); Regulatory pathway relevance (nda). The approval is a standard regulatory process for generics and does not indicate any compliance issues for existing products.
FDA AP — MIRABEGRON (ORIG)
FDAhigh relevance
Entity match (mirabegron); Regulatory pathway relevance (nda)
FDA document
View sourceFDA’s approval of Veklury (remdesivir) for the treatment of COVID-19—the science of safety and effectiveness
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View sourceShaping Community-based Pathway to Improve TB Surveillance Among African and Hindustan Immigrants Experiencing Vulnerabilities
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceA Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceREmifentanil And Dexmedetomidine for EarlY Intensive Blood Pressure Lowering in ICH.
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceA Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid.
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceUnconscious Mind Training
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceCollection of Pharmacokinetic Samples From People With Unanticipated Response, Significant Toxicity or Concern of Future Toxicity
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceU.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
Pfizerhigh relevance
Sponsor/company relevance (Pfizer)
FDA document
View sourceImmune correlates analysis in NextCOVE trial for a next-generation mRNA-1283 COVID-19 vaccine.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourceRNA polymerase II phosphorylation dynamics: from molecular mechanisms to human disease.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourceThe role of RNA modifications in cancer translational control.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourcePrecedents · guidance
Loading regulatory precedents…
View full regulatory analysisCompetitors · threats
Loading competitive findings…
View full competitive analysisThe FDA's approval of a generic version of Mirabegron by Deva Holding AS signifies increased competition in the overactive bladder market. This could impact pricing strategies and market share for existing branded products, necessitating close monitoring by portfolio teams.
The introduction of a generic may lead to price erosion for branded Mirabegron products, affecting revenue and market positioning.
The approval is a standard regulatory process for generics and does not indicate any compliance issues for existing products.
Monitor market uptake of the generic and any subsequent pricing strategies from competitors.
Track for follow-up milestones; no immediate action required.